0001562180-23-004959.txt : 20230608
0001562180-23-004959.hdr.sgml : 20230608
20230608160802
ACCESSION NUMBER: 0001562180-23-004959
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230606
FILED AS OF DATE: 20230608
DATE AS OF CHANGE: 20230608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROGERS MICHAEL W
CENTRAL INDEX KEY: 0001244159
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 231001958
MAIL ADDRESS:
STREET 1: C/O KERYX BIOPHARMACEUTICALS INC
STREET 2: ONE MARINA PARK DRIVE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0407
4
2023-06-06
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001244159
ROGERS MICHAEL W
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST ST.
CAMBRIDGE
MA
02142
true
false
false
false
false
Common Stock
2023-06-06
4
A
false
30000.00
0.00
A
96029.00
D
Stock Option (Right to buy)
1.20
2023-06-06
4
A
false
45000.00
0.00
A
2024-06-06
2033-06-06
Common Stock
45000.00
45000.00
D
The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Second Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
/s / Carolyn Rucci, attorney-in-fact for Michael W. Rogers
2023-06-08